Stocktoria
JUPITER NEUROSCIENCES, INC. JUNS
JUPITER NEUROSCIENCES, INC. (JUNS) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $21,796 at a -39662.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| JUNS | JUPITER NEUROSCIENCES, INC. | 2/9 | — | — | — |
| PRFX | PRF Technologies Ltd. | 4/9 | -14.88 | — | — |
| TLPH | TALPHERA, INC. | 4/9 | — | — | — |
| IBO | IMPACT BIOMEDICAL INC. | 3/9 | -2.38 | — | — |
| GNLX | GENELUX Corp | 2/9 | — | — | — |
| LYEL | Lyell Immunopharma, Inc. | 1/9 | -13.93 | — | — |
| ASBP | Aspire Biopharma Holdings, Inc. | 2/9 | — | — | — |
About JUPITER NEUROSCIENCES, INC.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
FAQ
Is JUNS financially healthy?
JUPITER NEUROSCIENCES, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does JUNS pay a dividend?
No, JUPITER NEUROSCIENCES, INC. does not currently pay a dividend.
How profitable is JUNS?
In FY2025, JUPITER NEUROSCIENCES, INC. had a net margin of -39662.8%.
Is JUNS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on JUPITER NEUROSCIENCES, INC.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.